Omos Biosciences decodes cancer progression signals to address the gap between early detection and actionable treatment. The company develops diagnostics that reliably predict which pre-cancers pose high risk, moving beyond simple detection. Their focus is on identifying clinically actionable danger signals to enable treatment at the pre-cancer stage.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments primarily focus on addressing the disease after it has developed, neglecting the potential for intervention during the early, pre-cancerous stages. This reactive approach limits therapeutic options and may result in less effective outcomes for patients.
Solution
Omos is developing a platform to identify and target the underlying mechanisms driving the transition from healthy cells to pre-cancerous states. By elucidating these early-stage processes, Omos aims to discover novel drug targets that can prevent or delay cancer development. Their technology seeks to shift the paradigm from treating established cancer to intervening in the pre-cancerous phase, offering the potential for more effective and preventative therapeutic strategies.
Target Audience
The primary audience includes pharmaceutical companies and research institutions focused on developing new cancer therapies and preventative treatments.
Features
- Identification of novel drug targets specific to pre-cancerous cells
- Elucidation of the molecular mechanisms driving early cancer development
- Platform for developing therapeutic interventions that target the pre-cancerous state